Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Osteoporosis Drug Stops Growth of Breast Cancer Cells, Even in Resistant Tumors

By BiotechDaily International staff writers
Posted on 03 Jul 2013
ADVERTISEMENT
SARTORIUS AG
A drug approved in Europe to treat osteoporosis has now been shown to suppress the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies.

Presented on June 15, 2013, at the annual Endocrine Society meeting in San Francisco (CA, USA), the findings demonstrate that the drug bazedoxifene triggers a formidable one-two punch that not only blocks estrogen from promoting breast cancer-cell growth, but also targets the estrogen receptor for destruction.

“We found bazedoxifene binds to the estrogen receptor and interferes with its activity, but the surprising thing we then found was that it also degrades the receptor—it gets rid of it,” said senior author Donald McDonnell, PhD, chair of Duke Cancer Institute’s (Durham, NC, USA) department of pharmacology and cancer biology.

In animal and cell culture studies, the drug suppressed growth both in estrogen-dependent breast cancer cells and in cells that had developed resistance to the antiestrogen tamoxifen and/or to the aromatase inhibitors, two of the most widely used types of drugs to prevent and treat estrogen-dependent breast cancer. Currently, if breast cancer cells develop resistance to these therapies, patients are usually treated with toxic chemotherapy agents that have significant side effects.

Bazedoxifene is an agent that, similar to tamoxifen, belongs to a class of drugs known as specific estrogen receptor modulators (SERMs). These drugs act like estrogen in some tissues, while substantially blocking estrogen action in other tissues. However, unlike tamoxifen, bazedoxifene has some of the characteristics of a newer group of drugs called selective estrogen receptor degraders (SERDs), which can target the estrogen receptor for destruction.

“Because the drug is removing the estrogen receptor as a target by degradation, it is less likely the cancer cell can develop a resistance mechanism because you are removing the target,” said lead author Suzanne Wardell, PhD, a research scientist working in McDonnell’s lab. Many researchers had presumed that once breast cancer cells developed resistance to tamoxifen; however, “We discovered that the estrogen receptor is still a good target, even after it resistance to tamoxifen has developed,” he said.

The investigators evaluated a range of breast cancer-cell types, including tamoxifen-sensitive cells that are resistant to the drug lapatinib; another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene. These cells had previously been shown to reactivate estrogen signaling in order to acquire drug resistance. In this cell type, bazedoxifene also strongly inhibited cell growth.

Ironically, in bone tissue, bazedoxifene mirrors the action of estrogen, helping protect it from destruction. Because bazedoxifene has already undergone safety and effectiveness studies as a treatment for osteoporosis, it may be a feasible near-term alternative for patients with advanced breast cancer whose tumors have become resistant to other treatment approaches, Dr. Wardell reported. In clinical trials, the most frequently reported side effect was hot flashes in the bazedoxifene treatment groups.

The study was funded by a research grant from Pfizer Pharmaceuticals (New York, NY, USA), maker of bazedoxifene.

Related Links:

Duke Cancer Institute





Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.